Viatris Inc.
$32.48B- Market cap
- $19.39B
- Debt
- +$14.41B
- Cash
- −$1.32B
Capital structure 57% equity / 43% debt · EV / Revenue 2.27x · EV / EBITDA 1393.83x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · Mkt capMarket cap $19.39B · View financials
Snapshot Sep 4, 4:00 PM ET
FY 2025 · Mkt cap
Decision snapshot: VTRS stock price at discount vs LH $16.88 current versus $23.66 implied using P/S multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at LH's multiple
Implied fair value · at VTRS's multiple
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Multiple premium
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: VTRS FY 2025 (ended Dec 31, 2025) · LH FY 2025 (ended Dec 31, 2025).
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 57% equity / 43% debt · EV / Revenue 2.27x · EV / EBITDA 1393.83x
Capital structure 83% equity / 17% debt · EV / Revenue 2.26x · EV / EBITDA 17.36x
VTRS carries the larger enterprise value at $32.48B against $31.56B; LH trades on the lower EV / Revenue multiple (2.26x vs 2.27x); LH on the lower EV / EBITDA (17.36x vs 1393.83x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
VIATRIS INC. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
LABCORP HOLDINGS INC. · implied price per share
Bear
$113.84
Base
$138.62
Bull
$182.73
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
0.98x
0.65x
Net debt / EBITDA
Leverage against operating earnings
561.72x
2.78x
Cash and equivalents
Liquid reserves on the balance sheet
$1.32B
$532.30M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
PFIZER INC
VTRS vs PFE
Organon & Co.
VTRS vs OGN
BRISTOL MYERS SQUIBB CO
VTRS vs BMY
AbbVie Inc.
VTRS vs ABBV
Merck & Co., Inc.
VTRS vs MRK
THERMO FISHER SCIENTIFIC INC.
VTRS vs TMO
DANAHER CORP /DE/
VTRS vs DHR
QUEST DIAGNOSTICS INC
VTRS vs DGX
WEST PHARMACEUTICAL SERVICES INC
VTRS vs WST
BAXTER INTERNATIONAL INC
VTRS vs BAX
MCKESSON CORP
VTRS vs MCK
$14.41B
$5.58B
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.